Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1997 Aug;71(8):6218–6224. doi: 10.1128/jvi.71.8.6218-6224.1997

Psi- vectors: murine leukemia virus-based self-inactivating and self-activating retroviral vectors.

K A Delviks 1, W S Hu 1, V K Pathak 1
PMCID: PMC191887  PMID: 9223521

Abstract

We have developed murine leukemia virus (MLV)-based self-inactivating and self-activating vectors to show that the previously demonstrated high-frequency direct repeat deletions are not unique to spleen necrosis virus (SNV) or the neomycin drug resistance gene. Retroviral vectors pKD-HTTK and pKD-HTpTK containing direct repeats composed of segments of the herpes simplex virus type 1 thymidine kinase (HTK) gene were constructed; in pKD-HTpTK, the direct repeat flanked the MLV packaging signal. The generation of hypoxanthine-aminopterin-thymidine-resistant colonies after one cycle of retroviral replication demonstrated functional reconstitution of the HTK gene. Quantitative Southern analysis indicated that direct repeat deletions occurred in 57 and 91% of the KD-HTTK and KD-HTpTK proviruses, respectively. These results demonstrate that (i) deletion of direct repeats occurs at similar high frequencies in SNV and MLV vectors, (ii) MLV psi can be efficiently deleted by using direct repeats, (iii) suicide genes can be functionally reconstituted during reverse transcription, and (iv) the psi region may be a hot spot for reverse transcriptase template switching events.

Full Text

The Full Text of this article is available as a PDF (304.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adam M. A., Ramesh N., Miller A. D., Osborne W. R. Internal initiation of translation in retroviral vectors carrying picornavirus 5' nontranslated regions. J Virol. 1991 Sep;65(9):4985–4990. doi: 10.1128/jvi.65.9.4985-4990.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Anderson W. F. End-of-the-year potpourri--1996. Hum Gene Ther. 1996 Dec 1;7(18):2201–2202. doi: 10.1089/hum.1996.7.18-2201. [DOI] [PubMed] [Google Scholar]
  3. Anderson W. F., McGarrity G. J., Moen R. C. Report to the NIH Recombinant DNA Advisory Committee on murine replication-competent retrovirus (RCR) assays (February 17, 1993). Hum Gene Ther. 1993 Jun;4(3):311–321. doi: 10.1089/hum.1993.4.3-311. [DOI] [PubMed] [Google Scholar]
  4. Burrows F. J., Thorpe P. E. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):8996–9000. doi: 10.1073/pnas.90.19.8996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Calos M. P., Lebkowski J. S., Botchan M. R. High mutation frequency in DNA transfected into mammalian cells. Proc Natl Acad Sci U S A. 1983 May;80(10):3015–3019. doi: 10.1073/pnas.80.10.3015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chong H., Vile R. G. Replication-competent retrovirus produced by a 'split-function' third generation amphotropic packaging cell line. Gene Ther. 1996 Jul;3(7):624–629. [PubMed] [Google Scholar]
  7. Cornetta K., Morgan R. A., Anderson W. F. Safety issues related to retroviral-mediated gene transfer in humans. Hum Gene Ther. 1991 Spring;2(1):5–14. doi: 10.1089/hum.1991.2.1-5. [DOI] [PubMed] [Google Scholar]
  8. Cornetta K. Safety aspects of gene therapy. Br J Haematol. 1992 Apr;80(4):421–426. doi: 10.1111/j.1365-2141.1992.tb04552.x. [DOI] [PubMed] [Google Scholar]
  9. Crystal R. G. Transfer of genes to humans: early lessons and obstacles to success. Science. 1995 Oct 20;270(5235):404–410. doi: 10.1126/science.270.5235.404. [DOI] [PubMed] [Google Scholar]
  10. Culver K. W. Clinical applications of gene therapy for cancer. Clin Chem. 1994 Apr;40(4):510–512. [PubMed] [Google Scholar]
  11. Culver K. W., Ram Z., Wallbridge S., Ishii H., Oldfield E. H., Blaese R. M. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science. 1992 Jun 12;256(5063):1550–1552. doi: 10.1126/science.1317968. [DOI] [PubMed] [Google Scholar]
  12. Culver K. W., Van Gilder J., Link C. J., Carlstrom T., Buroker T., Yuh W., Koch K., Schabold K., Doornbas S., Wetjen B. Gene therapy for the treatment of malignant brain tumors with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system. Hum Gene Ther. 1994 Mar;5(3):343–379. doi: 10.1089/hum.1994.5.3-343. [DOI] [PubMed] [Google Scholar]
  13. Dinges M. M., Cook D. R., King J., Curiel T. J., Zhang X. Q., Harrison G. S. HIV-regulated diphtheria toxin A chain gene confers long-term protection against HIV type 1 infection in the human promonocytic cell line U937. Hum Gene Ther. 1995 Nov;6(11):1437–1445. doi: 10.1089/hum.1995.6.11-1437. [DOI] [PubMed] [Google Scholar]
  14. Donahue R. E., Kessler S. W., Bodine D., McDonagh K., Dunbar C., Goodman S., Agricola B., Byrne E., Raffeld M., Moen R. Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J Exp Med. 1992 Oct 1;176(4):1125–1135. doi: 10.1084/jem.176.4.1125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Dougherty J. P., Temin H. M. A promoterless retroviral vector indicates that there are sequences in U3 required for 3' RNA processing. Proc Natl Acad Sci U S A. 1987 Mar;84(5):1197–1201. doi: 10.1073/pnas.84.5.1197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Eck S. L., Alavi J. B., Alavi A., Davis A., Hackney D., Judy K., Mollman J., Phillips P. C., Wheeldon E. B., Wilson J. M. Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a phase I trial. Hum Gene Ther. 1996 Aug 1;7(12):1465–1482. doi: 10.1089/hum.1996.7.12-1465. [DOI] [PubMed] [Google Scholar]
  17. Emerman M., Temin H. M. Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism. Cell. 1984 Dec;39(3 Pt 2):449–467. [PubMed] [Google Scholar]
  18. Günzburg W. H., Saller R. M., Salmons B. Retroviral vectors directed to predefined cell types for gene therapy. Biologicals. 1995 Mar;23(1):5–12. doi: 10.1016/1045-1056(95)90003-9. [DOI] [PubMed] [Google Scholar]
  19. Harrison G. S., Long C. J., Curiel T. J., Maxwell F., Maxwell I. H. Inhibition of human immunodeficiency virus-1 production resulting from transduction with a retrovirus containing an HIV-regulated diphtheria toxin A chain gene. Hum Gene Ther. 1992 Oct;3(5):461–469. doi: 10.1089/hum.1992.3.5-461. [DOI] [PubMed] [Google Scholar]
  20. Jang S. K., Davies M. V., Kaufman R. J., Wimmer E. Initiation of protein synthesis by internal entry of ribosomes into the 5' nontranslated region of encephalomyocarditis virus RNA in vivo. J Virol. 1989 Apr;63(4):1651–1660. doi: 10.1128/jvi.63.4.1651-1660.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Jang S. K., Kräusslich H. G., Nicklin M. J., Duke G. M., Palmenberg A. C., Wimmer E. A segment of the 5' nontranslated region of encephalomyocarditis virus RNA directs internal entry of ribosomes during in vitro translation. J Virol. 1988 Aug;62(8):2636–2643. doi: 10.1128/jvi.62.8.2636-2643.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Jorgensen R. A., Rothstein S. J., Reznikoff W. S. A restriction enzyme cleavage map of Tn5 and location of a region encoding neomycin resistance. Mol Gen Genet. 1979;177(1):65–72. doi: 10.1007/BF00267254. [DOI] [PubMed] [Google Scholar]
  23. Julias J. G., Hash D., Pathak V. K. E- vectors: development of novel self-inactivating and self-activating retroviral vectors for safer gene therapy. J Virol. 1995 Nov;69(11):6839–6846. doi: 10.1128/jvi.69.11.6839-6846.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Kawai S., Nishizawa M. New procedure for DNA transfection with polycation and dimethyl sulfoxide. Mol Cell Biol. 1984 Jun;4(6):1172–1174. doi: 10.1128/mcb.4.6.1172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Klatzmann D. Gene therapy for metastatic malignant melanoma: evaluation of tolerance to intratumoral injection of cells producing recombinant retroviruses carrying the herpes simplex virus type 1 thymidine kinase gene, to be followed by ganciclovir administration. Hum Gene Ther. 1996 Jan 20;7(2):255–267. doi: 10.1089/hum.1996.7.2-255. [DOI] [PubMed] [Google Scholar]
  26. Kun L. E., Gajjar A., Muhlbauer M., Heideman R. L., Sanford R., Brenner M., Walter A., Langston J., Jenkins J., Facchini S. Stereotactic injection of herpes simplex thymidine kinase vector producer cells (PA317-G1Tk1SvNa.7) and intravenous ganciclovir for the treatment of progressive or recurrent primary supratentorial pediatric malignant brain tumors. Hum Gene Ther. 1995 Sep;6(9):1231–1255. doi: 10.1089/hum.1995.6.9-1231. [DOI] [PubMed] [Google Scholar]
  27. Link C. J., Jr, Moorman D., Seregina T., Levy J. P., Schabold K. J. A phase I trial of in vivo gene therapy with the herpes simplex thymidine kinase/ganciclovir system for the treatment of refractory or recurrent ovarian cancer. Hum Gene Ther. 1996 Jun 10;7(9):1161–1179. doi: 10.1089/hum.1996.7.9-1161. [DOI] [PubMed] [Google Scholar]
  28. Mann R., Baltimore D. Varying the position of a retrovirus packaging sequence results in the encapsidation of both unspliced and spliced RNAs. J Virol. 1985 May;54(2):401–407. doi: 10.1128/jvi.54.2.401-407.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Martinez I., Dornburg R. Partial reconstitution of a replication-competent retrovirus in helper cells with partial overlaps between vector and helper cell genomes. Hum Gene Ther. 1996 Apr 10;7(6):705–712. doi: 10.1089/hum.1996.7.6-705. [DOI] [PubMed] [Google Scholar]
  30. Mikkelsen J. G., Lund A. H., Kristensen K. D., Duch M., Sørensen M. S., Jørgensen P., Pedersen F. S. A preferred region for recombinational patch repair in the 5' untranslated region of primer binding site-impaired murine leukemia virus vectors. J Virol. 1996 Mar;70(3):1439–1447. doi: 10.1128/jvi.70.3.1439-1447.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Miller A. D., Garcia J. V., von Suhr N., Lynch C. M., Wilson C., Eiden M. V. Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J Virol. 1991 May;65(5):2220–2224. doi: 10.1128/jvi.65.5.2220-2224.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Mizutani Y., Bonavida B., Yoshida O. Cytotoxic effect of diphtheria toxin used alone or in combination with other agents on human renal cell carcinoma cell lines. Urol Res. 1994;22(4):261–266. doi: 10.1007/BF00541904. [DOI] [PubMed] [Google Scholar]
  33. Mullen C. A., Coale M. M., Lowe R., Blaese R. M. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res. 1994 Mar 15;54(6):1503–1506. [PubMed] [Google Scholar]
  34. Mullen C. A., Kilstrup M., Blaese R. M. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):33–37. doi: 10.1073/pnas.89.1.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Mullen C. A. Metabolic suicide genes in gene therapy. Pharmacol Ther. 1994 Aug;63(2):199–207. doi: 10.1016/0163-7258(94)90046-9. [DOI] [PubMed] [Google Scholar]
  36. Olson P., Nelson S., Dornburg R. Improved self-inactivating retroviral vectors derived from spleen necrosis virus. J Virol. 1994 Nov;68(11):7060–7066. doi: 10.1128/jvi.68.11.7060-7066.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Olson P., Temin H. M., Dornburg R. Unusually high frequency of reconstitution of long terminal repeats in U3-minus retrovirus vectors by DNA recombination or gene conversion. J Virol. 1992 Mar;66(3):1336–1343. doi: 10.1128/jvi.66.3.1336-1343.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Onions D. Target and non-target effects of retrovirus vectors used for gene therapy and vaccination. Dev Biol Stand. 1995;84:59–74. [PubMed] [Google Scholar]
  39. Purcell D. F., Broscius C. M., Vanin E. F., Buckler C. E., Nienhuis A. W., Martin M. A. An array of murine leukemia virus-related elements is transmitted and expressed in a primate recipient of retroviral gene transfer. J Virol. 1996 Feb;70(2):887–897. doi: 10.1128/jvi.70.2.887-897.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Russ A. P., Friedel C., Grez M., von Melchner H. Self-deleting retrovirus vectors for gene therapy. J Virol. 1996 Aug;70(8):4927–4932. doi: 10.1128/jvi.70.8.4927-4932.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Sorscher E. J., Peng S., Bebok Z., Allan P. W., Bennett L. L., Jr, Parker W. B. Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines. Gene Ther. 1994 Jul;1(4):233–238. [PubMed] [Google Scholar]
  42. Temin H. M. Safety considerations in somatic gene therapy of human disease with retrovirus vectors. Hum Gene Ther. 1990 Summer;1(2):111–123. doi: 10.1089/hum.1990.1.2-111. [DOI] [PubMed] [Google Scholar]
  43. Uckert W., Walther W. Retrovirus-mediated gene transfer in cancer therapy. Pharmacol Ther. 1994 Sep;63(3):323–347. doi: 10.1016/0163-7258(94)90029-9. [DOI] [PubMed] [Google Scholar]
  44. Vanin E. F., Kaloss M., Broscius C., Nienhuis A. W. Characterization of replication-competent retroviruses from nonhuman primates with virus-induced T-cell lymphomas and observations regarding the mechanism of oncogenesis. J Virol. 1994 Jul;68(7):4241–4250. doi: 10.1128/jvi.68.7.4241-4250.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES